The European Medicines Agency said on Wednesday that 'benefit-risk remains positive' for AstraZeneca coronavirus vaccine. “One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin,” the European Medicines Agency (EMA) said.

EMA says 'benefit-risk remains positive' for AstraZeneca jab

European Medicines Agency (EMA) has once again reiterated its backing of the AstraZeneca COVID-19 vaccine after Germany suspended its use for people above the age of 60 years.

EMA sees 'no evidence' to restrict AstraZeneca vaccine amid suspensions

astrazeneca-corona-vaccine

Astrazeneca Corona Vaccine, News on Astrazeneca Corona Vaccine, stories on Astrazeneca Corona Vaccine, articles on Astrazeneca Corona Vaccine, Astrazeneca Corona Vaccine stories at Wion, Astrazeneca Corona Vaccine news, Astrazeneca Corona Vaccine latest news

astrazeneca corona-vaccine

EMA says 'benefit-risk remains positive' for AstraZeneca jab

EMA sees 'no evidence' to restrict AstraZeneca vaccine amid suspensions

EMA sees 'no evidence' to restrict AstraZeneca vaccine amid suspensions